Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Mohammad Sarif Mohiuddin
 -- 1591 2023-08-21 10:13:19 |
2 format correction
Dean Liu
 Meta information modification 1591 2023-08-22 02:27:16 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Akter, S.; Tasnim, S.; Barua, R.; Choubey, M.; Arbee, S.; Mohib, M.M.; Minhaz, N.; Choudhury, A.; Sarker, P.; Mohiuddin, M.S. The Effect of COVID-19 on Gut Microbiota. Encyclopedia. Available online: https://encyclopedia.pub/entry/48262 (accessed on 02 August 2024).
Akter S, Tasnim S, Barua R, Choubey M, Arbee S, Mohib MM, et al. The Effect of COVID-19 on Gut Microbiota. Encyclopedia. Available at: https://encyclopedia.pub/entry/48262. Accessed August 02, 2024.
Akter, Shamima, Sa’dia Tasnim, Rashu Barua, Mayank Choubey, Shahida Arbee, Mohammad Mohabbulla Mohib, Naofel Minhaz, Ajanta Choudhury, Pallab Sarker, Mohammad Sarif Mohiuddin. "The Effect of COVID-19 on Gut Microbiota" Encyclopedia, https://encyclopedia.pub/entry/48262 (accessed August 02, 2024).
Akter, S., Tasnim, S., Barua, R., Choubey, M., Arbee, S., Mohib, M.M., Minhaz, N., Choudhury, A., Sarker, P., & Mohiuddin, M.S. (2023, August 21). The Effect of COVID-19 on Gut Microbiota. In Encyclopedia. https://encyclopedia.pub/entry/48262
Akter, Shamima, et al. "The Effect of COVID-19 on Gut Microbiota." Encyclopedia. Web. 21 August, 2023.
The Effect of COVID-19 on Gut Microbiota
Edit
This entry is adapted from the peer-reviewed paper 10.3390/gidisord5030028

The COVID-19 pandemic caused by the SARS-CoV-2 virus has led to significant global health implications. Although the respiratory manifestations of COVID-19 are widely recognized, emerging evidence suggests that the disease may also significantly affect the gut microbiota, the intricate community of bacteria that lives within the gastrointestinal system.

COVID-19 gut microbiota microbiome dysbiosis

1. Introduction

The COVID-19 pandemic is a global health crisis caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a single-stranded enveloped positive-sense RNA virus with an average diameter of 75–150 nm that originated in Wuhan, China, at the end of 2019 and spread worldwide [1]. On 11 March 2020, the World Health Organization (WHO) declared COVID-19 a global pandemic [2], and to date, almost 7-million people have died from COVID-19 [3]. The virus predominantly affects the respiratory system, inducing a spectrum of symptoms that can range from mild-to-severe respiratory impairment, with several symptoms such as pyrexia, respiratory distress, pharyngitis, exhaustion, and myalgia [4]. In more severe cases, COVID-19 infection may lead to the development of pneumonia and acute respiratory distress syndrome (ARDS), which may require mechanical ventilation and lead to a significant risk of mortality [5].
In addition to respiratory manifestations, the pathogenesis of COVID-19 may result in systemic consequences such as the failure of multiple organs and physiological systems throughout the body [6]. COVID-19 manifests as inflammation of the cardiac muscle (myocarditis) [7] and vascular organs (endotheliitis), which increases the risk of blood clots, leading to pulmonary embolism and deep vein thrombosis [8]. Several reports have suggested that COVID-19 is associated with arrhythmia [9] and myocardial infarction [10]. A group of neurological manifestations has been observed in patients with COVID-19, including loss of taste and smell [11], generalized headache [12], dizziness with vertigo [13], seizures [14], encephalitis [15], and Guillain–Barré syndrome [16]. However, the exact mechanism underlying these effects is still under the laboratory bench. Several digestive system symptoms, such as nausea, vomiting, diarrhea, and acute abdominal tenderness, have been observed in some COVID-19 patients [17]. Renal impairment with acute renal injury is found in COVID-19 patients as a result of an inflammatory reaction by the body or a direct viral invasion of the kidneys [18].
The human gastrointestinal tract (GIT) is densely populated by the microbiota. The gut microbiota, a collection of bacteria, viruses, and fungi that live in the gastrointestinal tract, not only maintains mucosal immunity but also regulates the host’s systemic immune response [19]. Gut microbiota plays an important role in a broad range of physiological processes, from the digestion of complex polysaccharides to the regulation of neuronal signaling. In recent decades, it is getting more and more attention because of its association with a wide variety of diseases, ranging from metabolic disorders (e.g., diabetes and its complications) [20][21][22][23][24][25] to autoimmune diseases (such as rheumatoid arthritis, inflammatory bowel disease, and Type 1 diabetes), obesity [26], cancer [27], reproductive health [28][29][30], and sexual disorders [31][32], as well as neurodevelopmental disorders (e.g., autism) and neurodegenerative diseases (e.g., Alzheimer). Furthermore, modifying the microbiota in the human body may be a key factor for the treatment of disease. According to recent research on various respiratory disorders, gut microbiota may influence immunity and inflammation in the lungs [33].

2. Understanding the Composition and Diversity of the Gut Microbiota

Around 100-trillion microorganisms (bacteria, fungi, viruses, protozoa, and viruses) are found in the human gut. The human genome is made up of 23,000 genes, while the microbiome encodes over 3-million genes that produce more than thousands of metabolites, impacting human health [34]. The composition and metabolism of the adult gut microbial communities are affected by a combination of factors, including diet, demographics, use of medication, health status, and environmental components shaping the gut environment [35][36][37]. Humans can be herbivorous, carnivorous, etc., depending on the culture, food supply, etc. The diversity of the distinctive microbes of each habitat varies considerably, even in healthy individuals, with a high specialization of niches within and between individuals. According to the Human Microbiome Project Consortium, the overall fecal microbiota richness was estimated to be 226 bacterial genera among 208 donors [38]. The microbiota of the human gut is dominated by two major phyla: Bacteroidetes and Firmicutes [39][40].

3. Factors Influencing Gut Microbiota Composition, Including Diet, Lifestyle, and Medications

The intestinal microbiota is integral to human halobionts. Past studies have shown that various factors, such as diet and drugs, play an important role in the composition and diversity of the intestinal microbiome [34][41][42]. Dietary patterns, as well as individual foods, can directly influence the diversity of the microbiome. Artificial sweeteners (sucralose, aspartame, saccharin) significantly increased Bacteroides, Clostridia, and other aerobic bacteria in the gut. Food additives like emulsifiers in processed food reduced microbial diversity and increased inflammation promoting Proteobacteria [43][44]. Popular food-restrictive diets (vegan, raw food, gluten-free diets) can also impact gut microbial diversity. Some studies have shown the advantages of a vegan diet over an omnivorous diet, but others have not proven this theory [45]. Apart from food, drugs are also a key factor in the gut microbiota composition. Drugs such as proton pump inhibitors have a significant impact on microbial composition, which could explain the higher levels of gastrointestinal infection in people consuming these drugs. Antibiotics are impacting the intestinal microbiome [46]. Earlier observational human studies have shown an obesogenic effect in humans, even at low doses of antibiotics on food [47]. A Westernized lifestyle, such as behaviors, habits, and dietary patterns, may involve the alteration of gut microbiota. This lifestyle, which is characterized by a high intake of processed food, fructose corn syrup as an alternative of sugar, and unhealthy fats, was found to result in a higher prevalence of severe COVID-19 cases. Dietary habits can lead to underlying health conditions such as obesity, diabetes, and cardiovascular disorders, which are associated with the advancement of the diseases [48]. Several supplements such as Vitamin C, D, and zinc received attention due to their potential immune-boosting properties [49]. However, some studies suggested the effects of these supplements were inconclusive, and they are not proven cures or preventatives for COVID-19 [50].

4. Gut Microbiota Alterations in COVID-19 Patients

Several research investigations have explored alterations in gut microbiota in COVID-19 patients, illuminating the possible involvement of the gut microbiome in relation to the illness. The aforementioned investigation insights into the association between COVID-19 and gut microbiota dysbiosis, as well as its potential implications for the severity and treatment of the disease. A study conducted by Zuo et al. (2020) examined the gut microbiota composition in COVID-19 patients. The researchers observed a substantial reduction of beneficial commensal bacteria, such as Bifidobacterium and Lactobacillus, along with a corresponding increase in opportunistic pathogens, such as Clostridium hathewayi [51]. Another study conducted by Gu and colleagues in 2020 reported that the alteration of gut microbiota decreased the amount of butyrate-producing bacterial species, which are well-known for their potential anti-inflammatory effects.
Furthermore, investigations observed that patients with COVID-19 exhibit a reduction of microbial diversity. A study by Zuo et al. (2021) showed a reduction in the prevalence of bacterial species linked to elevated microbial diversity in COVID-19 cases, in comparison with subjects without any underlying health conditions. The connection between a decline in microbial diversity and higher vulnerability to inflammatory illnesses and infections implies that it may be involved in the development of COVID-19 [52]. Interestingly, modifications in the gut microbiota have also been correlated with the severity of COVID-19. According to Yeoh and colleagues’ investigation conducted in 2021, it was identified that severe cases of COVID-19 were distinguished by a condition of gut dysbiosis, resulting in a decline in the presence of beneficial bacteria while allowing for an overgrowth of potential pathogens [53]. In another investigation conducted by Gu et al. in 2020, it was observed that patients with more severe symptoms have a discernible variation in the composition of their gut microbiota in relation to those experiencing milder symptoms [54]. These studies suggest a possible association between dysbiosis and the severity of symptoms associated with COVID-19.
Dysbiosis in the gut microbiota can lead to impaired regulation of the immune response, elevated systemic inflammation, and increased susceptibility to respiratory infections. Several studies have indicated that the dysbiosis of gut microbiota may play a role in the pro-inflammatory conditions witnessed in severe cases of COVID-19. Dhar and Mohanty (2021) reported that the alteration of pro-inflammatory cytokine levels observed in COVID-19 patients, accompanied by the evidence of gut dysbiosis, suggests a potential mechanism by which the gut microbiota influences the variability in disease outcomes [55].
The gut microbiota has recently been identified as a promising diagnostic and prognostic indicator for COVID-19. Researchers have identified specific microbial indicators that enable differentiation between individuals afflicted with COVID-19 from healthy individuals. Qin Liu and colleagues developed a diagnostic model based on gut microbiota demonstrating high efficacy in discerning patients with COVID-19 from those without the infection. Moreover, specific microbial profiles have demonstrated a correlation with the severity of diseases, proposing that gut microbiota analysis could serve as a promising prognostic tool [56].
It is important to consider that the treatment of COVID-19 has a significant effect on gut microbiota. The administration of antibiotics and antiviral agents has been reported to potentially disturb microbial equilibrium, which may ultimately worsen dysbiosis. A study by Lucie et al. reported in 2022 that COVID-19 patients receiving antibiotics had greater dysbiosis compared to those not receiving antibiotics, suggesting the need for prudent administration of antimicrobial agents to ameliorate the potential adverse effects on the gut microbiota [57]. Yeoh and colleagues observed correlations between specific gut microbial taxa and inflammatory markers such as C-reactive protein (CRP) and cytokines with pro-inflammatory properties [53].
Research investigating gut microbiota alterations in COVID-19 patients has elucidated the phenomenon of dysbiosis, a decline in microbial diversity, and potential associations with the severity of the illness. The role of gut microbiota in modulating the immune response and impact of systemic inflammation emphasizes its significance in the pathogenesis of COVID-19.

References

  1. Wang, M.-Y.; Zhao, R.; Gao, L.-J.; Gao, X.-F.; Wang, D.-P.; Cao, J.-M. SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development. Front. Cell. Infect. Microbiol. 2023, 10, 587269.
  2. Aubert, O.; Yoo, D.; Zielinski, D.; Cozzi, E.; Cardillo, M.; Dürr, M.; Domínguez-Gil, B.; Coll, E.; Da Silva, M.I.; Sallinen, V.; et al. COVID-19 pandemic and worldwide organ transplantation: A population-based study. Lancet Public Health 2021, 6, e709–e719.
  3. WHO Coronavirus (COVID-19) Dashboard. Available online: https://covid19.who.int/ (accessed on 6 June 2023).
  4. Majumder, J.; Minko, T. Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19. AAPS J. 2021, 23, 14.
  5. Aslan, A.; Aslan, C.; Zolbanin, N.M.; Jafari, R. Acute respiratory distress syndrome in COVID-19: Possible mechanisms and therapeutic management. Pneumonia 2021, 13, 14.
  6. Paidas, M.J.; Sampath, N.; Schindler, E.A.; Cosio, D.S.; Ndubizu, C.O.; Shamaladevi, N.; Kwal, J.; Rodriguez, S.; Ahmad, A.; Kenyon, N.S.; et al. Mechanism of Multi-Organ Injury in Experimental COVID-19 and Its Inhibition by a Small Molecule Peptide. Front. Pharmacol. 2023, 13, 864798.
  7. Davis, M.G.; Bobba, A.; Chourasia, P.; Gangu, K.; Shuja, H.; Dandachi, D.; Farooq, A.; Avula, S.R.; Shekhar, R.; Sheikh, A.B. COVID-19 Associated Myocarditis Clinical Outcomes among Hospitalized Patients in the United States: A Propensity Matched Analysis of National Inpatient Sample. Viruses 2022, 14, 2791.
  8. Xu, S.-W.; Ilyas, I.; Weng, J.-P. Endothelial dysfunction in COVID-19: An overview of evidence, biomarkers, mechanisms and potential therapies. Acta Pharmacol. Sin. 2022, 44, 695–709.
  9. Mohammad, M.; Emin, M.; Bhutta, A.; Gul, E.H.; Voorhees, E.; Afzal, M.R. Cardiac arrhythmias associated with COVID-19 infection: State of the art review. Expert Rev. Cardiovasc. Ther. 2021, 19, 881–889.
  10. Zuin, M.; Rigatelli, G.; Battisti, V.; Costola, G.; Roncon, L.; Bilato, C. Increased risk of acute myocardial infarction after COVID-19 recovery: A systematic review and meta-analysis. Int. J. Cardiol. 2023, 372, 138–143.
  11. Javed, N.; Ijaz, Z.; Khair, A.H.; Dar, A.A.; Lopez, E.D.; Abbas, R.; Sheikh, A.B. COVID-19 loss of taste and smell: Potential psychological repercussions. Pan Afr. Med. J. 2022, 43, 38.
  12. Tana, C.; Bentivegna, E.; Cho, S.-J.; Harriott, A.M.; García-Azorín, D.; Labastida-Ramirez, A.; Ornello, R.; Raffaelli, B.; Beltrán, E.R.; Ruscheweyh, R.; et al. Long COVID headache. J. Headache Pain 2022, 23, 93.
  13. Korres, G.; Kitsos, D.K.; Kaski, D.; Tsogka, A.; Giannopoulos, S.; Giannopapas, V.; Sideris, G.; Tyrellis, G.; Voumvourakis, K. The Prevalence of Dizziness and Vertigo in COVID-19 Patients: A Systematic Review. Brain Sci. 2022, 12, 948.
  14. Nikbakht, F.; Mohammadkhanizadeh, A.; Mohammadi, E. How does the COVID-19 cause seizure and epilepsy in patients? The potential mechanisms. Mult. Scler. Relat. Disord. 2023, 46, 102535.
  15. Siow, I.; Lee, K.S.; Zhang, J.J.Y.; Saffari, S.E.; Ng, A. Encephalitis as a neurological complication of COVID-19: A systematic review and meta-analysis of incidence, outcomes, and predictors. Eur. J. Neurol. 2023, 28, 3491–3502.
  16. Khan, F.; Sharma, P.; Pandey, S.; Sharma, D.; Vijayavarman, V.; Kumar, N.; Shukla, S.; Dandu, H.; Jain, A.; Garg, R.K.; et al. COVID-19-associated Guillain-Barre syndrome: Postinfectious alone or neuroinvasive too? J. Med. Virol. 2023, 93, 6045–6049.
  17. Groff, A.; Kavanaugh, M.; Ramgobin, D.; McClafferty, B.; Aggarwal, C.S.; Golamari, R.; Jain, R. Gastrointestinal Manifestations of COVID-19: A Review of What We Know. Ochsner J. 2021, 21, 177–180.
  18. Faour, W.H.; Choaib, A.; Issa, E.; El Choueiry, F.; Shbaklo, K.; Alhajj, M.; Sawaya, R.T.; Harhous, Z.; Alefishat, E.; Nader, M. Mechanisms of COVID-19-induced kidney injury and current pharmacotherapies. Inflamm. Res. 2021, 71, 39–56.
  19. Abid, M.B. Could the menagerie of the gut microbiome really cure cancer? Hope or hype. J. Immunother. Cancer 2019, 7, 92.
  20. Mohiuddin, M.S.; Himeno, T.; Inoue, R.; Miura-Yura, E.; Yamada, Y.; Nakai-Shimoda, H.; Asano, S.; Kato, M.; Motegi, M.; Kondo, M.; et al. Glucagon-Like Peptide-1 Receptor Agonist Protects Dorsal Root Ganglion Neurons against Oxidative Insult. J. Diabetes Res. 2019, 2019, 9426014.
  21. Mohib, M.; Rabby, S.F.; Paran, T.Z.; Hasan, M.; Ahmed, I.; Hasan, N.; Sagor, A.T.; Mohiuddin, S. Protective role of green tea on diabetic nephropathy—A review. Cogent Biol. 2016, 2, 1248166.
  22. Mohiuddin, M.S.; Himeno, T.; Yamada, Y.; Morishita, Y.; Kondo, M.; Tsunekawa, S.; Kato, Y.; Nakamura, J.; Kamiya, H. Glucagon Prevents Cytotoxicity Induced by Methylglyoxal in a Rat Neuronal Cell Line Model. Biomolecules 2021, 11, 287.
  23. Tasnim, S.; Auny, F.M.; Hassan, Y.; Yesmin, R.; Ara, I.; Mohiuddin, M.S.; Kaggwa, M.M.; Gozal, D.; Mamun, M.A. Antenatal depression among women with gestational diabetes mellitus: A pilot study. Reprod. Health 2022, 19, 71.
  24. Motegi, M.; Himeno, T.; Nakai-Shimoda, H.; Inoue, R.; Ozeki, N.; Hayashi, Y.; Sasajima, S.; Mohiuddin, M.S.; Asano-Hayami, E.; Kato, M.; et al. Deficiency of glucagon gene-derived peptides induces peripheral polyneuropathy in mice. Biochem. Biophys. Res. Commun. 2020, 532, 47–53.
  25. Choubey, M.; Ranjan, A.; Krishna, A. Adiponectin/AdipoRs signaling as a key player in testicular aging and associated metabolic disorders. Vitam. Horm. 2021, 115, 611–634.
  26. Dai, W.; Choubey, M.; Patel, S.; Singer, H.A.; Ozcan, L. Adipocyte CAMK2 deficiency improves obesity-associated glucose intolerance. Mol. Metab. 2021, 53, 101300.
  27. Barua, R.; Mizuno, K.; Tashima, Y.; Ogawa, M.; Takeuchi, H.; Taguchi, A.; Okajima, T. Bioinformatics and Functional Analyses Implicate Potential Roles for EOGT and L-fringe in Pancreatic Cancers. Molecules 2021, 26, 882.
  28. Choubey, M. Growth Hormone and Insulin-like Growth Factor-I: Novel Insights into the Male Reproductive Health. Growth Disord. Acromegaly 2020, 6, 113–128.
  29. Ranjan, A.; Choubey, M.; Yada, T.; Krishna, A. Nesfatin-1 ameliorates type-2 diabetes-associated reproductive dysfunction in male mice. J. Endocrinol. Investig. 2019, 43, 515–528.
  30. Choubey, M.; Ranjan, A.; Bora, P.S.; Krishna, A. Protective role of adiponectin against testicular impairment in high-fat diet/streptozotocin-induced type 2 diabetic mice. Biochimie 2020, 168, 41–52.
  31. Ranjan, A.; Choubey, M.; Yada, T.; Krishna, A. Immunohistochemical localization and possible functions of nesfatin-1 in the testis of mice during pubertal development and sexual maturation. Histochem. J. 2019, 50, 533–549.
  32. Choubey, M.; Ranjan, A.; Bora, P.S.; Baltazar, F.; Krishna, A. Direct actions of adiponectin on changes in reproductive, metabolic, and anti-oxidative enzymes status in the testis of adult mice. Gen. Comp. Endocrinol. 2019, 279, 1–11.
  33. Dang, A.T.; Marsland, B.J. Microbes, metabolites, and the gut–lung axis. Mucosal Immunol. 2019, 12, 843–850.
  34. Huttenhower, C.; Gevers, D.; Knight, R.; Abubucker, S.; Badger, J.H.; Chinwalla, A.T.; Creasy, H.H.; Earl, A.M.; FitzGerald, M.G.; Fulton, R.S.; et al. Structure, function and diversity of the healthy human microbiome. Nature 2012, 486, 207–214.
  35. Thompson-Chagoyán, O.C.; Maldonado, J.; Gil, A. Colonization and impact of disease and other factors on intestinal microbiota. Dig. Dis. Sci. 2007, 52, 2069–2077.
  36. Lozupone, C.; Faust, K.; Raes, J.; Faith, J.J.; Frank, D.N.; Zaneveld, J.; Gordon, J.I.; Knight, R. Identifying genomic and metabolic features that can underlie early successional and opportunistic lifestyles of human gut symbionts. Genome Res. 2012, 22, 1974–1984.
  37. Claesson, M.J.; Jeffery, I.B.; Conde, S.; Power, S.E.; O’Connor, E.M.; Cusack, S.; Harris, H.M.B.; Coakley, M.; Lakshminarayanan, B.; O’Sullivan, O.; et al. Gut microbiota composition correlates with diet and health in the elderly. Nature 2023, 488, 178–184.
  38. Li, K.; Bihan, M.; Methé, B.A. Analyses of the Stability and Core Taxonomic Memberships of the Human Microbiome. PLoS ONE 2023, 8, e63139.
  39. Ley, R.E.; Bäckhed, F.; Turnbaugh, P.; Lozupone, C.A.; Knight, R.D.; Gordon, J.I. Obesity alters gut microbial ecology. Proc. Natl. Acad. Sci. USA 2005, 102, 11070–11075.
  40. Ley, R.E.; Turnbaugh, P.J.; Klein, S.; Gordon, J.I. Human Gut Microbes Associated with Obesity. Nature 2006, 444, 1022–1023.
  41. Rothschild, D.; Weissbrod, O.; Barkan, E.; Kurilshikov, A.; Korem, T.; Zeevi, D.; Costea, P.I.; Godneva, A.; Kalka, I.N.; Bar, N.; et al. Environment dominates over host genetics in shaping human gut microbiota. Nature 2018, 555, 210–215.
  42. Gacesa, R.; Kurilshikov, A.; Vila, A.V.; Sinha, T.; Klaassen, M.A.Y.; Bolte, L.A.; Andreu-Sánchez, S.; Chen, L.; Collij, V.; Hu, S.; et al. Environmental factors shaping the gut microbiome in a Dutch population. Nature 2022, 604, 732–739.
  43. Sacha, J.; Sacha, M.; Soboń, J.; Borysiuk, Z.; Feusette, P. Is It Time to Begin a Public Campaign Concerning Frailty and Pre-frailty? A Review Article. Front. Physiol. 2023, 8, 484.
  44. Chassaing, B.; Koren, O.; Goodrich, J.K.; Poole, A.C.; Srinivasan, S.; Ley, R.E.; Gewirtz, A.T. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature 2015, 519, 92–96.
  45. Wu, G.D.; Compher, C.; Chen, E.Z.; Smith, S.A.; Shah, R.D.; Bittinger, K.; Chehoud, C.; Albenberg, L.G.; Nessel, L.; Gilroy, E.; et al. Comparative metabolomics in vegans and omnivores reveal constraints on diet-dependent gut microbiota metabolite production. Gut 2016, 65, 63–72.
  46. Jackson, M.A.; Goodrich, J.K.; Maxan, M.-E.; Freedberg, D.E.; Abrams, J.A.; Poole, A.C.; Sutter, J.L.; Welter, D.; Ley, R.E.; Bell, J.T.; et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut 2016, 65, 749–756.
  47. Blaser, M.J. Antibiotic use and its consequences for the normal microbiome. Science 2016, 352, 544–545.
  48. Holly, J.M.P.; Biernacka, K.; Maskell, N.; Perks, C.M. Obesity, Diabetes and COVID-19: An Infectious Disease Spreading from the East Collides with the Consequences of an Unhealthy Western Lifestyle. Front. Endocrinol. 2020, 11, 582870.
  49. Firouzi, S.; Pahlavani, N.; Navashenaq, J.G.; Clayton, Z.S.; Beigmohammadi, M.T.; Malekahmadi, M. The effect of Vitamin C and Zn supplementation on the immune system and clinical outcomes in COVID-19 patients. Clin. Nutr. Open Sci. 2022, 44, 144–154.
  50. Thomas, S.; Patel, D.; Bittel, B.; Wolski, K.; Wang, Q.; Kumar, A.; Il’giovine, Z.J.; Mehra, R.; McWilliams, C.; Nissen, S.E.; et al. Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection. JAMA Netw. Open 2023, 4, e210369.
  51. Zuo, T.; Zhang, F.; Lui, G.C.Y.; Yeoh, Y.K.; Li, A.Y.L.; Zhan, H.; Wan, Y.; Chung, A.C.K.; Cheung, C.P.; Chen, N.; et al. Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization. Gastroenterology 2020, 159, 944–955.e948.
  52. Zuo, T.; Liu, Q.; Zhang, F.; Lui, G.; Tso, E.; Yeoh, Y.K.; Chen, Z.; Boon, S.; Chan, F.K.L.; Chan, P.; et al. Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19. Gut 2021, 70, 276–284.
  53. Yeoh, Y.K.; Zuo, T.; Lui, G.C.-Y.; Zhang, F.; Liu, Q.; Li, A.Y.; Chung, A.C.; Cheung, C.P.; Tso, E.Y.; Fung, K.S.; et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut 2021, 70, 698–706.
  54. Gu, S.; Chen, Y.; Wu, Z.; Chen, Y.; Gao, H.; Lv, L.; Guo, F.; Zhang, X.; Luo, R.; Huang, C.; et al. Alterations of the Gut Microbiota in Patients with Coronavirus Disease 2019 or H1N1 Influenza. Clin. Infect. Dis. 2020, 71, 2669–2678.
  55. Dhar, D.; Mohanty, A. Gut microbiota and Covid-19- possible link and implications. Virus Res. 2020, 285, 198018.
  56. Liu, Q.; Su, Q.; Zhang, F.; Tun, H.M.; Mak, J.W.Y.; Lui, G.C.-Y.; Ng, S.S.S.; Ching, J.Y.L.; Li, A.; Lu, W.; et al. Multi-kingdom gut microbiota analyses define COVID-19 severity and post-acute COVID-19 syndrome. Nat. Commun. 2022, 13, 6806.
  57. Bernard-Raichon, L.; Venzon, M.; Klein, J.; Axelrad, J.E.; Zhang, C.; Sullivan, A.P.; Hussey, G.A.; Casanovas-Massana, A.; Noval, M.G.; Valero-Jimenez, A.M.; et al. Gut microbiome dysbiosis in antibiotic-treated COVID-19 patients is associated with microbial translocation and bacteremia. Nat. Commun. 2022, 13, 5926.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Gastroenterology & Hepatology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Shamima Akter
,
Sa’dia Tasnim
,
Rashu Barua
,
Mayank Choubey
,
Shahida Arbee
,
Mohammad Mohabbulla Mohib
,
Naofel Minhaz
,
Ajanta Choudhury
,
Pallab Sarker
,
Mohammad Sarif Mohiuddin
View Times: 130
Revisions: 2 times (View History)
Update Date: 22 Aug 2023
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback